Dr. Jenette Creaney

Biography

Jenette Creaney is the Scientific Director of the NHMRC Centre for Research Excellence at the National Centre for Asbestos-Related Diseases, leading a team of 35 researchers focused on developing novel therapies and methods for detecting and preventing asbestos-related diseases. She heads the Biomarkers Discovery unit at NCARD and manages the NCARD Biobank, the largest collection of clinical specimens from patients with pleural disease, including mesothelioma and lung cancer. Creaney completed her undergraduate studies at the University of Western Australia and received her PhD in 1995 from La Trobe University, Australia. Following her postdoctoral fellowship at the University of Cincinnati Medical Centre in Ohio, USA, she returned to Australia in 1999, specializing in cancer immunology as a molecular biologist and protein chemist. Her research interests include biomarker discovery and validation, neoantigen-targeted immunotherapy for mesothelioma and lung cancer, and she has been involved in significant international collaborations, including the Cancer Genome Atlas, to identify new biomarkers and diagnostic strategies for mesothelioma. Her work aims to improve patient outcomes through sophisticated immunological predictions and personalized treatment approaches based on the genetic and protein profiles of tumors.

Research Interests

Experience